Eli Lilly and Company (LLY)vsNanobiotix (NBTX)
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
NBTX
Nanobiotix
$35.46
-3.93%
HEALTHCARE · Cap: $1.93B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 221570% more annual revenue ($72.25B vs $32.59M). LLY leads profitability with a 35.0% profit margin vs -73.5%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
NBTX
Avoid22
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Revenue surging 186.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -198.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : NBTX
The strongest argument for NBTX centers on Revenue Growth, Debt/Equity. Revenue growth of 186.8% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : NBTX
The primary concerns for NBTX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while NBTX is a hypergrowth play — different risk/reward profiles.
NBTX carries more volatility with a beta of 0.58 — expect wider price swings.
NBTX is growing revenue faster at 186.8% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 22/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Nanobiotix
HEALTHCARE · BIOTECHNOLOGY · USA
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?